- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104’s path to U.S...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.61 | -0.830383882385 | 73.46 | 79.72 | 73 | 162 | 73.48980198 | CS |
4 | 4.28 | 6.2417967041 | 68.57 | 79.72 | 67.68 | 272 | 70.26422086 | CS |
12 | -6.71 | -8.43388637506 | 79.56 | 80.29 | 65.04 | 1377 | 70.01141192 | CS |
26 | -11.66 | -13.7971837652 | 84.51 | 93.06 | 65.04 | 941 | 74.33039261 | CS |
52 | -20.54 | -21.993789485 | 93.39 | 93.39 | 65.04 | 1328 | 82.40839374 | CS |
156 | 11.34 | 18.4360266623 | 61.51 | 93.39 | 53 | 1416 | 73.85804193 | CS |
260 | -2.05 | -2.73698264352 | 74.9 | 93.39 | 43.38 | 2768 | 63.02882408 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.